Amgen erythropoietin patents infringed upon by Transkaryotic, Aventis, court says

By Jennifer Chiou

New York, Aug. 3 - Amgen Inc. said that the Court of Appeals for the Federal Circuit affirmed the District Court's decision that Transkaryotic Therapies Inc. and Aventis Pharmaceuticals Inc. infringe Amgen's erythropoietin patent estate.

The Thousand Oaks, Calif., developer of human therapeutics said that the court's decision upheld the validity of two of Amgen's erythropoietin patents as well as the infringement by Transkaryotic of three patents and 12 claims, including a patent that does not expire until 2015.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.